Show simple item record

dc.contributor.authorVerbaanderd, Ciskaen_US
dc.contributor.authorMaes, Hanneloreen_US
dc.contributor.authorSchaaf, Marco Ben_US
dc.contributor.authorSukhatme, Vikas Pen_US
dc.contributor.authorPantziarka, Panen_US
dc.contributor.authorSukhatme, Vidulaen_US
dc.contributor.authorAgostinis, Patriziaen_US
dc.contributor.authorBouche, Gauthieren_US
dc.date.accessioned2018-01-18T02:29:13Z
dc.date.issued2017en_US
dc.identifier.citationVerbaanderd, Ciska, Hannelore Maes, Marco B Schaaf, Vikas P Sukhatme, Pan Pantziarka, Vidula Sukhatme, Patrizia Agostinis, and Gauthier Bouche. 2017. “Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents.” ecancermedicalscience 11 (1): 781. doi:10.3332/ecancer.2017.781. http://dx.doi.org/10.3332/ecancer.2017.781.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34651936
dc.description.abstractChloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the treatment of cancer. Overall, preclinical studies support CQ and HCQ use in anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the therapeutic activity. Thus far, clinical results are mostly in favour of the repurposing of CQ. However, over 30 clinical studies are still evaluating the activity of both CQ and HCQ in different cancer types and in combination with various standard treatments. Interestingly, CQ and HCQ exert effects both on cancer cells and on the tumour microenvironment. In addition to inhibition of the autophagic flux, which is the most studied anti-cancer effect of CQ and HCQ, these drugs affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 pathway in cancer cells. In the tumour stroma, CQ was shown to affect the tumour vasculature, cancer-associated fibroblasts and the immune system. The evidence reviewed in this paper indicates that both CQ and HCQ deserve further clinical investigations in several cancer types. Special attention about the drug (CQ versus HCQ), the dose and the schedule of administration should be taken in the design of new trials.en
dc.language.isoen_USen
dc.publisherCancer Intelligenceen
dc.relation.isversionofdoi:10.3332/ecancer.2017.781en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718030/pdf/en
dash.licenseLAAen_US
dc.subjectRepurposing Drugs in Oncology (ReDO) projecten
dc.subjectdrug repositioningen
dc.subjectchloroquine (CQ)en
dc.subjecthydroxychloroquine (HCQ)en
dc.subjectneoplasmsen
dc.subjectantineoplastic agentsen
dc.subjectanti-malarial agentsen
dc.titleRepurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agentsen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalecancermedicalscienceen
dash.depositing.authorSukhatme, Vikas Pen_US
dc.date.available2018-01-18T02:29:13Z
dc.identifier.doi10.3332/ecancer.2017.781*
dash.authorsorderedfalse
dash.contributor.affiliatedSukhatme, Vikas


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record